Microcap Ledger Veru Inc. $VERU
Facts as of . Built from SEC filings and our own data. Small caps move fast; check the latest filings.
Snapshot
- Exchange
- Nasdaq Capital Market
- Sector
- Pharmaceutical Preparations
- Headquarters
- Miami, FL
- Fiscal year end
- September 30
- Shares outstanding
- 17,050,320 [10-Q 2026-08-10]
What the company doesAI summary of filing
Veru Inc. is a late-stage clinical biopharmaceutical company focused on developing medicines for cardiometabolic and inflammatory diseases. The company has two primary drug candidates: enobosarm, an oral selective androgen receptor modulator in planned Phase 2b clinical trials to preserve muscle mass and increase fat loss in obese patients receiving GLP-1 receptor agonists, and sabizabulin, a microtubule disruptor in planned Phase 2 trials for treating inflammation in atherosclerotic cardiovascular disease. The company is currently pre-revenue with respect to its pharmaceutical pipeline; it sold its FDA-approved FC2 Female Condom product on December 30, 2024, and has ceased commercial revenue from that product line. [10-K 2025-12-17]
Financial health
| Period | Revenue | Net income | Operating cash flow | Cash | Filing |
|---|---|---|---|---|---|
| 9 months to Jun 2026 | — | −$15.06M | −$20.55M | $23.88M | [10-Q 2026-08-10] |
| FY ended Sep 2025 | — | −$22.73M | −$30.04M | $15.79M | [10-K 2025-12-17] |
| FY ended Sep 2024 | $16.89M | −$37.80M | −$21.68M | $24.92M | [10-K 2024-12-16] |
- Quarterly cash burn
- −$6.85M
- Cash runway Estimate
- ~10.5 months
Capital structure and dilution
| Date | Shares outstanding | Filing |
|---|---|---|
| 2024-12-12 | 146,383,920 | [10-K 2024-12-16] |
| 2025-02-10 | 146,383,920 | [10-Q 2025-02-13] |
| 2025-05-05 | 146,583,920 | [10-Q 2025-05-08] |
| 2025-08-07 | 14,650,392 | [10-Q 2025-08-12] |
| 2025-12-12 | 16,050,320 | [10-K 2025-12-17] |
| 2026-02-06 | 16,050,320 | [10-Q 2026-02-11] |
| 2026-05-08 | 16,050,320 | [10-Q 2026-05-13] |
| 2026-08-06 | 17,050,320 | [10-Q 2026-08-10] |
- Shelf registration
- S-3 filed 2026-04-07; declared effective 2026-04-15 [S-3 2026-04-07]
Listing status
Current status: 1 Form 8-K Item 3.01 filing(s) in the last 24 months, most recent 2025-02-28. Item 3.01 covers delisting notices, failures to meet a listing rule and listing transfers; read the filing for which one.
| Date | Event | Details | Deadline | Filing |
|---|---|---|---|---|
| 2025-02-28 | 8-K Item 3.01 | Notice of delisting or failure to satisfy a continued listing rule or standard; or transfer of listing | — | [8-K 2025-02-28] |
Who owns it
| Date | Insider | Type | Shares | Price | Filing |
|---|---|---|---|---|---|
| 2026-08-13 | Barnette K Gary | buy | 1,800 | $2.69 | [4 2026-08-17] |
Catalysts and calendar
| Date | Type | Title |
|---|---|---|
| 2026-09-08 | 8-K | Other events |
| 2026-08-10 | 10-Q | Quarterly report |
| 2026-08-10 | 8-K | Results of operations |
| 2026-07-02 | 8-K | Material agreement entered |
| 2026-07-02 | 424B5 | Prospectus or prospectus supplement |
| 2026-06-04 | 8-K | Other events |
| 2026-05-13 | 10-Q | Quarterly report |
| 2026-05-13 | 8-K | Results of operations |
| 2026-04-07 | S-3 | Registration statement |
| 2026-04-07 | S-3 | Registration statement |
| 2026-03-13 | 8-K | Director or officer change; Shareholder vote results |
| 2026-02-17 | 13G | Beneficial ownership report (5%+ holder) |
Alerts for $VERU
Email me when Veru Inc. files an offering, gets a deficiency notice, or moves sharply.
Facts as of . Small caps move fast; check the latest filings.